Obeticholic Acid

• CAT Number: I003604
• CAS Number: 459789-99-2
• Molecular Formula: C26H44O4
• Molecular Weight: 420.63
• Purity: 98%
• Synonyms: (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• Target: FXR
• Target Protein: Q96RI1
• Solubility: DMSO: ≥ 35 mg/mL
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: EC50: 99 nM (FXR)
• IUPAC Name: (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acidcid
• InChI: InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
• InChIKey: ZXERDUOLZKYMJM-ZWECCWDJSA-N
• SMILES: CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O

Obeticholic acid（Cat No.:I003604）is a synthetic bile acid analogue used for the treatment of primary biliary cholangitis (PBC), a chronic liver disease. It works by activating the farnesoid X receptor (FXR), which regulates bile acid production and reduces liver inflammation and fibrosis. Obeticholic acid helps decrease bile acid accumulation, improving liver function and slowing disease progression in patients with PBC who do not respond adequately to ursodeoxycholic acid (UDCA). Its unique mechanism offers an effective option for managing PBC, potentially reducing the need for liver transplantation in advanced cases.

Overview of Clinical Research

INT-747 is a Farnesoid X-activated receptor agonist. It has been granted for the orphan drug status in Primary biliary cirrhosis; Primary sclerosing cholangitis.

Reference

1:FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. Ghebremariam YT, Yamada K, Lee JC, Johnson CL, Atzler D, Anderssohn M, Agrawal R, Higgins JP, Patterson AJ, Böger RH, Cooke JP.PLoS One. 2013 Apr 4;8(4):e60653. doi: 10.1371/journal.pone.0060653. Print 2013. PMID: 23593273 Free PMC Article
2:Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M.J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):80-92. doi: 10.1016/j.jsbmb.2012.02.007. Epub 2012 Mar 8. PMID: 22406511